QUEST DIAGNOSTICS INC

Quest Diagnostics’ Rule 144 filing shows a small, compliant insider sale—no material ownership shift, just routine governance and liquidity‑boosting action.

Quest Diagnostics Q2 2026 beats estimates, lifts revenue and EPS, upgrades outlook, and sees share price near 52‑week high as analysts raise targets.

Quest Diagnostics’ phantom‑stock deal reveals how executive incentives tie to shareholder value and highlights the company’s AI and automation plans to boost margins and speed in a fast‑growing diagnostics market.

Quest Diagnostics’ decade‑long stock growth, AI‑powered diagnostics, and at‑home testing reveal how the lab services leader outpaces peers and drives shareholder value in today’s evolving health ecosystem.

Quest Diagnostics’ latest earnings reveal strong cost‑control, revenue growth, and a forward‑looking focus on emerging markets, digital health, and cybersecurity—insights investors should watch.

Quest Diagnostics shares soar with a new dividend, 14%+ CAGR and AI‑driven labs—learn how the company’s tech, margin growth and payer strategy power investor returns.

Quest Diagnostics’ $500 M 5% senior note issuance gives it the capital to boost high‑margin molecular tests, automate labs, and expand patient access while keeping debt‑service risk low.

Quest Diagnostics raises $500 M with 5% senior notes due 2036 to fund growth, refinance debt and boost shareholder value.

Quest Diagnostics’ latest earnings reveal a shift toward high‑margin, tech‑enabled testing—underlying growth, cost‑efficiency, and regulatory challenges that could reshape its valuation and investor outlook.

Quest Diagnostics Q1 2026: revenue & earnings rise, cost‑saving “Invigorate” fuels profitability, AI‑driven diagnostics & a Michigan acquisition boost growth.